Thousands monitored: is the whooping cough vaccine safe in real life?

NCT ID NCT07444502

Completed ⭐️ VACCINE ⭐️ Sponsor: BioNet-Asia Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tracked over 10,000 people in Thailand who received the Boostagen® vaccine, which protects against tetanus, diphtheria, and whooping cough. Healthcare workers reported any side effects to see how safe the vaccine is in everyday use. The study also looked at pregnant women and their newborns to check for any complications. The goal is to ensure the vaccine remains safe after being approved for the public.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Boostagen® (combined tetanus, diphtheria, and acellular pertussis vaccine)
What this could lead to: If successful, this study will confirm that Boostagen® is safe for widespread use, including in pregnant women, helping protect against whooping cough, tetanus, and diphtheria.
What could go wrong: This is an observational safety study, not a test of effectiveness. It may not detect rare side effects, and results are specific to Thailand's population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIPHTHERIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diphtheria prevention target pertussis prevention target tetanus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIPHTHERIA PERTUSSIS (WHOOPING COUGH) TETANUS

Contacts and locations

Locations

BioNet-Asia Co., Ltd.

Bangkok, 10260, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.